Forte Biosciences, Inc. (FBRX)

Forte Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	58.22	76.96	22.24	37.13	41.1	42.04
Short-Term Investments	-	-	36.12	-	-	-
Cash & Short-Term Investments	58.22	76.96	58.37	37.13	41.1	42.04
Cash Growth	26.97%	31.86%	57.21%	-9.67%	-2.25%	-28.45%
Other Current Assets	6.89	3.63	2.98	1.2	0.41	0.48
Total Current Assets	65.11	80.59	61.35	38.33	41.51	42.52
Net Property, Plant & Equipment	0.11	0.13	0.08	0.11	-	-
Other Long-Term Assets	2	2.06	0.14	0.54	0.49	0.79
Total Assets	67.22	82.78	61.56	38.98	42	43.31
Accounts Payable	13.08	9.99	4.88	1.42	1.15	0.95
Accrued Expenses	12.04	11.8	4.2	2.24	2.03	0.81
Total Current Liabilities	23.65	20.75	9.08	3.67	3.18	1.76
Total Liabilities	25.12	21.79	9.08	3.67	3.18	1.76
Shareholders' Equity	42.1	60.99	52.48	35.31	38.82	41.55
Total Liabilities & Equity	67.22	82.78	61.56	38.98	42	43.31
Net Cash (Debt)	58.22	76.96	58.37	37.13	41.1	42.04
Net Cash Growth	-24.34%	31.86%	57.21%	-9.67%	-2.25%	-28.45%
Net Cash Per Share	3.57	5.23	20.02	29.40	59.11	75.25
Book Value	42.1	60.99	52.48	35.31	38.82	41.55
Book Value Per Share	2.58	4.14	18.00	27.96	55.83	74.36
Tangible Book Value	42.1	60.99	52.48	35.31	38.82	41.55
Tangible Book Value Per Share	2.58	4.14	18.00	27.96	55.83	74.36

Updated May 11, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q